A new mobility ecosystem will personalize every journey by 2030
27.4.2023 09:35:00 EEST | Business Wire | Press release
Management and technology consultancy BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. The study, Mobility 2030, says all players will battle over customer and value chain data, and service offerings must address national as well as urban and rural demand patterns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005716/en/
BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. (Graphic: Business Wire)
“The automotive industry must respond to the human-centric mobility trend to stay ahead of the competition by maintaining its strategic position as the prime touchpoint to the customer. The industry must provide customers with truly personalized offerings, focus on collecting complex data to derive actionable insights, and orchestrate an ecosystem of partners that embraces new technologies,” said Dr. Stefan Penthin, Global Leader Automotive and Industrial Manufacturing at BearingPoint.
The study is the first in a series of three on mobility and drew from BearingPoint’s internal research, the views of clients across all industry segments and input from the consultancy’s segment and technology leaders. While the automotive industry is the focus, the study examines how all segments will be active in the new mobility ecosystem, from manufacturers and transportation providers to energy suppliers, government organizations, and insurance companies.
By 2030, the study projects that approximately 23% of all megacity trips will be through shared, on-demand mobility offerings (up from just 8% in 2021). By 2030, each player will be part of a demanding new infrastructure and alliance-ecosystem relationships that deliver multimodal journeys with diverse powertrains. Mobility will be consumed as a service, so access to data will be key. On-demand services mean all players will compete to acquire, analyze, and exploit customer data so they can react to changing travel patterns.
“In the journey to 2030, the transportation experience will become individualized, and new infrastructure, services, and relationships will be needed. Providers must be more user-centered and cater to rural and urban demands. Ultimately both utility companies and public transportation organizations will have a new and larger role,” said Marion Schulte, Global Leader Utilities, Postal and Transportation at BearingPoint.
Mobility that maximizes security, personal well-being, and sustainability
Various modes of travel will become integrated, enabling urban and rural intermodal transport hubs. Customers will demand mobility that maximizes security, personal well-being, and sustainability. Risk profiles will diverge for different usage and regions, the study foresees. According to EU statistics, 17 of the 20 busiest air routes in Europe cover distances of less than 434 miles, distances where intercity trains can offer faster, cleaner, and more sustainable journeys.
“As citizens demand greater availability, quality, and flexibility from mobility services, public transportation policy will evolve. Governments should ensure equal access to transport networks for all citizens, and the various modes of travel must be carefully integrated with safety, security, and personal well-being key priorities. Mobility policies should also be designed to maximize citizens productivity, both in terms of working and non-working time,” said Andrew Montgomery, Global Leader Government and Public Sector.
For more details and insights, you can download the study here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030-what-happens-when-every-journey-is-personalized/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005716/en/
Contact information
Press contact
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
